NCT03503149招募中不适用
Molecular Tumor Board at the Center for Personalized Medicine Tübingen: a Prospective Observational Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Progression-free survival
研究概览
简要总结
Molecular Tumor Board at the Center for Personalized Medicine
详细描述
Molecular Tumor Board at the Center for Personalized Medicine The study objectives are
- To ensure a prospective documentation of all patients who are referred to the Molecular Tumor Board in routine clinical care
- To prospectively ensure the documentation of MTB patients with an emphasis to clinical outcome parameters progression-free survival (PFS), overall survival (OS) and further response assessments (e.g. peripheral immunmonitoring, imaging parameters)
- To prospectively assess patient-reported outcome of MTB patients
- To evaluate compliance to MTB suggestions in routine clinical care
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Given informed consent ("broad consent" of the University Hospital Tübingen)
- •≥ 18 years of age
- •Clinical indication for a referral to Molecular Tumor Board by the treating physician
排除标准
- •The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients
结局指标
主要结局
Progression-free survival
时间窗: 6 months
Progression-free survival
次要结局
- Overall survival(an average of 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
UWCCC Molecular Tumor Board RegistryHematologic NeoplasmsSolid NeoplasmNCT03023202University of Wisconsin, Madison10,000
招募中
不适用
Molecular Tumor Board - A Registry of the East German Hematology and Oncology Study Group.hematologic or oncologic diseasesDRKS00032977Martin-Luther-Universität Halle-Wittenberg250
招募中
不适用
Register study of the Molecular Tumor Board (tumor entity-spanning molecular characterization program to evaluate individualized tumor biology-guided therapy in adults with rare and advanced tumor entities)Cross-tumor entity (adult patients = 18 years of age with any advanced tumor disease or with rare tumor entity (incidence of less than one case per 100,000 population)).N/ADRKS00025847niversitätsklinikum Freiburg Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation1,000
招募中
不适用
Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) ProjectSolid TumorNCT02806388National Cancer Centre, Singapore5,500
招募中
不适用
The Cancer Molecular Screening and Therapeutics (MoST) Program-ScreeningCancer - Any cancerCancerACTRN12616000908437niversity of Sydney7,628